معرفی
Richard Pomerantz is a Professor in the Department of Biochemistry and Molecular Biology at Thomas Jefferson University's College of Life Sciences, based at the Bluemle Life Sciences Building in Philadelphia.
Dr. Pomerantz's research centers on DNA repair mechanisms and their dual roles in maintaining genome integrity in healthy cells and driving genome instability in cancer. His laboratory investigates mutagenic double-strand break repair pathways—particularly alternative end-joining—which promote proliferation in BRCA1/2-mutated cancer cells. Key focuses include developing DNA polymerase theta inhibitors as targeted therapies for BRCA-deficient cancers (breast, ovarian, leukemias) and pioneering novel DNA/RNA synthetic biotechnologies. His work also explores RNA's potential roles in DNA repair and the interplay between RNA and DNA metabolism.
Analysis of Dr. Pomerantz's recent publications reveals a concentrated effort on DNA polymerase theta (Polθ) as a therapeutic target, spanning structural biology, inhibitor development, and clinical applications. His research demonstrates strong synergy between Polθ inhibitors and PARP inhibitors in cancer treatment, while extending to nucleoside analogs for hematologic malignancies through replicative stress induction.
Information regarding Dr. Pomerantz's student advising and research grants was not provided in available sources.
Dr. Pomerantz leads an active laboratory focused on translating DNA repair pathway discoveries into personalized cancer therapeutics, with particular emphasis on exploiting synthetic lethality in homology-directed repair-deficient cancers.
